Every parliamentary written question tabled by Daisy Cooper this session, with the full answer and department. See how every department answers, or back to the MP page.
Showing 121–140 of 150 · Department of Health and Social Care
With reference to the conclusions of the report entitled Transplant care in the UK: a patient perspective, published by Kidney Care UK in July 2024, if he will take steps to ensure people who have
The Department, NHS England, and NHS Blood and Transplant are working together to implement the recommendations of the Organ Utilisation Group’s 2023 report through the Implementation Steering Group for Organ Utilisation. The recommendations state that ps...
With reference to the conclusions of the report entitled Transplant care in the UK: a patient perspective, published by Kidney Care UK in July 2024, if he will take steps to ensure all chronic kidn
The Department, NHS England, and NHS Blood and Transplant are working together to implement the recommendations of the Organ Utilisation Group’s 2023 report through the Implementation Steering Group for Organ Utilisation. The recommendations state that ps...
How many staff have left the NHS ophthalmic sector to join ophthalmic units in independent treatment centres.
The Department does not hold the information requested.
Whether he has made an assessment of the adequacy of the value for money of ophthalmic care in independent treatment centres.
It is the responsibility of individual commissioners to commission services and agree contracts most suitable for their local context. Contracts between commissioners and providers must comply with the NHS Payment Scheme, a set of prices and rules used to...
With reference to the conclusions of the report entitled Transplant care in the UK: a patient perspective, published by Kidney Care UK in July 2024, if he will take steps to ensure that eligible ki
NHS England’s Service Specification for Renal Transplantation identifies transplant as the optimal treatment option for patients with stage five chronic kidney disease (CKD 5) and mandates that all commissioned providers should assess the benefits and ris...
What steps his Department has taken to help reduce waiting lists for a kidney transplant.
NHS Blood and Transplant (NHSBT) manage the NHS Organ Donor Register and National Transplant Register in the United Kingdom. They are working to reduce the number of patients on the waiting list by revising the National Organ Retrieval Service to improve ...
What data his Department (a) collects and (b) holds on the number of people waiting for places in hospices run by charitable organisations.
We want a society where every person, as well as their families and carers, receives high-quality, compassionate care, from diagnosis through to end of life.I recently met NHS England and discussions have begun on how to reduce inequalities and variation ...
Whether hospice funding will be included in his Department's 10-year plan for health and care.
We want a society where every person, as well as their families and carers, receives high-quality, compassionate care, from diagnosis through to end of life.I recently met NHS England and discussions have begun on how to reduce inequalities and variation ...
Pursuant to the Answer of 9 September 2024 to Question 3791 on Respiratory Syncytial Virus: Vaccination, whether he has received any advice from the Joint Committee on Vaccination and Immunisation
The Joint Committee on Vaccination and Immunisation (JCVI) has not provided advice on whether the respiratory syncytial virus (RSV) vaccine should be extended to children over the age of one year with spinal muscular atrophy type 1.The JCVI considered a r...
If he will commission research to (a) track and (b) compare international access to myeloma treatments; whether his Department holds data on the use by other countries of isatuximab in combination
The Department has no plans to commission research to compare international access to myeloma treatments. There are a number of independent publications that compare international access to new medicines, including cancer medicines, such as the European F...
With reference to the Dental recruitment incentive scheme 2024/25 published on 10 May 2024, how many NHS dentists have been recruited on the Golden Hello pathway in each (a) region and (b) ICB area
The dentistry recovery plan, Faster, simpler and fairer: our plan to recover and reform NHS dentistry, published on 7 February 2024, included a Golden Hello scheme offering up to 240 dentists a cash incentive to deliver National Health Service work in und...
If he will make an assessment of the effectiveness of (a) Genomics England Limited and (b) the NHS Genomic Medicine Service in (i) stimulating and (ii) facilitating research activity.
The NHS Genomic Medicine Service (NHS GMS), in partnership with Genomics England (GEL), delivers a national whole genome sequencing service, as part of routine care for rare disease and cancer patients. GEL delivers the National Genomic Research Library (...
If he will make it his policy to extend the covid-19 booster vaccination this autumn to (a) unpaid and (b) young carers.
The primary aim of the autumn 2024 COVID-19 vaccination programme remains the prevention of severe illness, hospitalisations, and deaths, arising from COVID-19. On 2 August 2024 the Government accepted the advice of the independent Joint Committee on Vacc...
What the evidential basis is for not extending the respiratory syncytial virus immunisation programme to all children under the age of one year.
There are currently no approved respiratory syncytial virus vaccines for children under the age of one year. This is a dynamic area and the Joint Committee on Vaccination and Immunisation, supported by The UK Health Security Agency, is continuing to keep ...
Whether he (a) has had and (b) plans to have discussions with the National Institute for Health and Care Excellence on (i) its use of the new severity modifier and (ii) how it (A) measures and (B)
We have received briefings on the use of the severity modifier by the National Institute for Health and Care Excellence (NICE), in the development of its guidance for the National Health Service, on whether new medicines should be routinely funded by the ...
Whether the National Institute for Health and Care Excellence has made a recent assessment of the potential impact of the removal of the end-of-life modifier on cancer technology appraisals.
We have received briefings on the use of the severity modifier by the National Institute for Health and Care Excellence (NICE), in the development of its guidance for the National Health Service, on whether new medicines should be routinely funded by the ...
If he will make it his policy to conduct a review of prescribing rights during this Parliament.
In late 2020, NHS England launched a series of public consultations seeking views on proposals to amend the responsibilities for the prescribing, supply, and administration of medicines for the following professionals:- dental hygienists and dental therap...
How many applicants were (a) accepted onto and (b) rejected from the NHS Scientist Training Programme in (i) 2021-2022, (ii) 2022-2023 and (iii) 2023-2024.
The following table shows the total number of annual starters in the NHS Scientist Training Programme, as well as their split by the in-service and direct entry routes, and the number of rejected or unsuccessful direct entry applicants, each year from 202...
How many myeloma patients are receiving a fourth line treatment; and what proportion of those patients are being treated with isatuximab in combination with pomalidomide and dexamethasone.
Information on the number of myeloma patients receiving a fourth line treatment is not held centrally. However, the following table shows the number of patients notified to receive isatuximab, in combination with pomalidomide and dexamethasone, in 2021, 2...
If he will make representations to (a) Daiichi Sankyo and (b) AstraZeneca following the decision by NICE not to recommend Enhertu as a cost effective treatment for advanced stage breast cancer.
Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE), on the basis of an evaluation of a treatment’s costs and benefits. The NICE’s methods are internationally respected, and have been developed through extensive work with industry, academics, and the public, to ensure they appropriately capture the costs and benefits, and best reflect social values. These are very difficult decisions to make, and it is important that they are made independently, and on the basis of the available evidence.We understand that despite the NICE instigating an exceptional pause in the process to allow for commercial negotiations to take place with the companies Daiichi Sankyo and AstraZeneca, a deal to enable patient access to this treatment on the NHS in England has not been reached.We know the NICE’s announcement has come as a blow to many women and their families. The NICE and NHS England have already sought to apply as much flexibility as they can in their considerations of Enhertu for HER2 LOW breast cancer, and have made it clear to the companies that their pricing of the drug remains the main obstacle to access.Within 16 weeks of the publication of final guidance, companies can also request a rapid review to consider new patient access scheme proposals, with the aim of establishing a pricing agreement that would improve cost-effectiveness and enable patient access to high-cost medicines. The Government wants to see a deal reached to make Enhertu available. The NICE and NHS England remain open to considering an improved offer from the companies through the rapid review process, and we strongly encourage the companies to come back to the table.